mercaptopurine – mercaptopurine tablets 50 mg 25 pcs pack

$28.00

Description

Latin name

Mercaptopurin

Release form

tablets

Packaging

25 pcs

Pharmacological action

Mercaptopurin has an antitumor, immunosuppressive effect.

Indications

Acute lymphoblastic leukemia, acute myelogenous leukemia (including acute myelocytic leukemia), exacerbation of chronic myelogenous leukemia, uterine chorionepithelioma, reticulosis, chronic granulocytic leukemia.

Contraindications

Hypersensitivity, tumor resistance, inhibition of bone marrow function (leukopenia with a white blood cell count less than 3 · 109 / l, thrombocytopenia with a platelet count less than 100 · 109 / l), chickenpox, shingles and other infections, a history of kidney, gout, or kidney stone disease.

Use during pregnancy and lactation

Contraindicated in pregnancy. The use of mercaptopurine during pregnancy was accompanied by an increased risk of miscarriage or premature birth.

Breastfeeding should be discontinued during treatment.

Composition of

1 tablet contains:

Active ingredient: mercaptopurine 50 mg

Dosage and administration of

mercaptopurine is taken orally. For adults and children, the initial oral dose is 2.5 mg / kg / day or 80-100 mg / m2 (on average, 100-200 mg for adults, 50 mg for children 5 years of age). It is possible to increase the dose to 5 mg / kg / day (no more) for 4 weeks. Maintenance dose: 1.5-2.5 mg / kg or 50-100 mg / m2 per day. Patients with hepatic and / or renal failure reduce the dose. When administered concomitantly with allopurinol (300-600 mg / day), only 1 / 3-1 / 4 of the usual dose of mercaptopurine is used (decrease in metabolic rate due to xanthine oxidase blockade).

The daily dose of mercaptopurine is usually used once.

Also used in combination chemotherapy.

Side effects

From the nervous system and sensory organs: headache, weakness.

From the side of the cardiovascular system and blood: most often anemia, leukopenia, thrombocytopenia (during the period of active therapy for acute myelogenous leukemia in patients, a period of relative bone marrow aplasia is often noted, while it is important to carry out appropriate supportive treatment).

From the gastrointestinal tract: nausea, vomiting, diarrhea, loss of appetite, hepatotoxic effect (has a toxic allergic genesis and more often occurs when a dose is higher than 2.5 mg / kg / day) or cholestasis (scleral or skin yellowness) rarely – stomatitis ( usually at high doses), ulcerations in the digestive tract, hepatic encephalopathy.

From the genitourinary system: less often – hyperuricemia or nephropathy.

From the skin: hyperpigmentation of the skin, skin rash, itching.

Other: decreased immunity and susceptibility to infections.

Storage conditions

In the dark place at a temperature of no higher than 20 ° C.

Term hodnosty

5 years

Deystvuyuschee substances

mercaptopurine

pharmacy terms of prescription

Form of Treatment

tablets